Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boston Scientific Corporation has completed the sale of its cardiac surgery and vascular surgery businesses to the Getinge Group of Sweden for $750 million in cash.
Subscribe to our email newsletter
The company expects to record after-tax charges of approximately $240 million in connection with the transaction.
Jim Tobin, president and CEO of Boston Scientific, said: “We have now sold three of our five previously identified non-strategic businesses, and we expect to close on the remaining two, fluid management and venous access, this quarter. These divestitures, along with our ongoing efforts to reduce expenses and simplify our operating model, should help us achieve our overall goals of restoring profitable growth, increasing shareholder value and strengthening Boston Scientific for the future.”